



# ANZBMS

9 -12 November,  
Cairns Australia

# 2025



DELEGATE  
HANDBOOK



ANZBMS

## PLATINUM SPONSOR



## GOLD SPONSOR



## SILVER SPONSOR



## COFFEE CART SPONSOR



## SYMPOSIUM SPONSOR



## EXHIBITORS



## DESTINATION SPONSOR



## AIRLINE PARTNER



---

## CONTENTS

---

<b>CONTENTS</b>	<b>2</b>
<b>WELCOME FROM THE PRESIDENT</b>	<b>3</b>
<b>SOCIETY SECRETARIATS</b>	<b>3</b>
<b>ANZBMS 2025 COMMITTEE</b>	<b>4</b>
<b>ANZBMS OFFICE BEARERS 2025</b>	<b>4</b>
<b>PAST ANZBMS OFFICE BEARERS 1988-2023</b>	<b>4</b>
SPONSORS & AWARDS OF THE AUSTRALIAN & NEW ZEALAND BONE & MINERAL SOCIETY .....	5
<b>DELEGATE INFORMATION</b>	<b>12</b>
<b>INVITED PLENARY SPEAKERS</b>	<b>17</b>
<b>INVITED SYMPOSIUM SPEAKERS</b>	<b>17</b>
<b>POSTER LISTING</b>	<b>32</b>
PLENARY POSTERS (PLENARY ROOM 1 & 2) .....	32
POSTER TOUR 1 - TOP 5 CLINICAL & BASIC SCIENCE POSTERS (TRINITY MEZZANINE) .....	32
ANZBMS POSTER SESSION 1 - ODD NUMBERS (TRINITY MEZZANINE) .....	33
POSTER TOUR 2 - TOP 5 CLINICAL & BASIC SCIENCE POSTERS (TRINITY MEZZANINE) .....	35
ANZBMS POSTER SESSION 2 - EVEN NUMBERS & NORDIN POSTER VIEWING (TRINITY MEZZANINE) .....	35
<b>SPONSOR AND TRADE PARTICIPANTS</b>	<b>38</b>
PLATINUM SPONSOR .....	39
GOLD SPONSOR .....	39
EXHIBITORS .....	40

---

## WELCOME FROM THE PRESIDENT

---

As President, I am delighted to welcome you to the annual scientific meeting of the ANZBMS being held at the Cairns Convention and Exhibition Centre. Our POC chairs, Agnes Arthur, Kirtan Ganda and their team have put together a wonderful program spanning basic, translational and clinical science in the bone and mineral field. We have international speakers from North America, Europe and Japan and also Emma Duncan, an Aussie who is President of one of our partner societies, ASBMR. These are in addition to plenary speakers from New Zealand and Australia and presenters of oral communications and posters of outstanding research submitted as abstracts. There are also Early Career Investigator sessions and supplementary workshops, not least an update on DXA and related technologies.

The main themes of the program include:

**Metabolic regulation of bone**

**Osteocyte mechano-responses**

**OMICS**

**Transgender bone health**

**Dental tissue regeneration**

**Bone health in the setting of diabetes mellitus**

**Bone health in the Australian indigenous population**

**Menopausal Hormone Therapy**

I'm sure that you'll be engrossed by everything in the program and we are all looking forward to the ANZBMS Debate which will determine whether 'Nutritional therapy is better than pharmacotherapy for prevention of bone loss in the older adult'.

Complementing the scientific program are evening activities including our welcome reception, clinical case sessions and the conference dinner which takes place in a unique and spectacular setting.

Whether you are an early or mid-career investigator, clinician, basic scientist, or allied health professional, the meeting will allow you to reconnect with peers, drive new collaborations and learn from the exciting program of cutting-edge musculoskeletal science.

Welcome to Cairns and the ASM of ANZBMS.

Professor Mark Cooper

President of ANZBMS

---

## SOCIETY SECRETARIATS

---

### **ANZBMS**

Ivone Johnson

[ijohnson@anzbms.org.au](mailto:ijohnson@anzbms.org.au)

[www.anzbms.org.au](http://www.anzbms.org.au)

### **Conference Secretariat – ASN Events**

Aileen Lozie

[Aileen.l@asnevents.net.au](mailto:Aileen.l@asnevents.net.au)

[www.asn.events](http://www.asn.events)



## ANZBMS 2025 COMMITTEE

**Dr. Agnes Arthur**  
The University of Adelaide  
ANZBMS POC Co-Chair

**A/Prof Kirtan Ganda**  
Concord Repatriation General Hospital  
ANZBMS POC Co-Chair

**Dr Eugenie Macfarlane**  
Acting ECIC Co-Chair and ECIC Events Subcommittee Member  
The University of Sydney

**Dr Cassandra Smith**  
Past ECIC Co-Chair and ECI Representative for POC  
Deakin University

**Kara Anderson**  
Past ECIC Co-Chair and ECI Representative for POC  
Deakin University

## ANZBMS OFFICE BEARERS 2025

**ANZBMS President**  
ANZBMS President Elect  
  
ANZBMS Treasurer  
ANZBMS Past President

Prof Mark Cooper  
A/Prof Michelle McDonald  
Prof Rachel Davey  
Prof Mark Forwood

**ANZBMS Councillors**  
Dr Melissa Cantley, A/Prof Cherie Chiang,  
Prof Belinda Beck, Prof Itamar Levinger, Dr Marc Sim

## PAST ANZBMS OFFICE BEARERS 1988-2023

YEAR	PRESIDENT	VICE PRESIDENT PRESIDENT ELECT	SECRETARY	TREASURER	COUNCILLORS
1990 - Steering Group	T.J.Martin		M.Hooper		A.Need, R.Prince, J.Eisman, I.Reid, K.Ibbertson, D.Fraser, P.Sambrook, E.Seeman
1991-93 - Inaugural Council	T.J.Martin		M.Hooper	M.Hooper	J.Eisman, A.Goulding, D.Perry-Keen, J.Wark, A.Need, N.Kent
1993-95	J.Eisman	I.Reid	N.Kent	J.Wark	P.Sambrook, A.Need, R.Prince, D.Perry-Keene, E.Seeman
1995-97	I.Reid	N.Kent	J.Moseley	P.Ebeling	P.Sambrook, A.Need, R.Prince, D.Perry-Keene
1997-99	N.Kent	P.Ebeling	J.Moseley	P.Ebeling	R.Prince, I.Reid, M.Hooper, H.Morris, M.Forwood
1999-01	P.Ebeling	M.Hooper	J.Cornish	M.Forwood	J.Moseley, H.Morris, E.Mackie, M.Zheng
2001-03	M.Hooper	E.Seeman	J.Cornish	M.Forwood	R.Mason, R.Price, D.Findlay, G.Nicholson
2003-05	E.Seeman	J.Cornish	D.Findlay	M.Forwood	R.Mason, R.Price, G.Nicholson, P.Sambrook
2005-07	J. Cornish	P. Sambrook	D. Findlay	R. Price	R. Mason, G. Nicholson, P. Nash, M. Gillespie
2007-09	P. Sambrook	R. Mason	M. Gillespie	R. Price	P. Nash, N. Fazzalari, M. Kotowicz, T. Cundy
2009-11	R. Mason	M. Gillespie	N. Fazzalari	R. Price	P. Sambrook, N. Sims, M. Seibel, G. Thomas, N. Gilchrist
2011-13	M.Gillespie	M. Seibel	G. Atkins	G. Thomas	N. Sims, M. Bolland, C. Inderjeeth, N. Pocock, R. Mason
2013-15	M. Seibel	E. Duncan	G. Atkins	G. Thomas	N. Sims, M. Gillespie, N. Pocock, N. Pavlos, E. Dennison

YEAR	PRESIDENT	VICE PRESIDENT PRESIDENT ELECT	SECRETARY	TREASURER	COUNCILLORS
2015 - 17	E. Duncan	P. Croucher	P. Anderson	N. Pavlos	R. Daley, R Buchbinder, N. Pocock, A. Pettit, E. Dennison
2017 – 19	P.Croucher	N.Sims	P.Anderson	N.Pavlos	A.Pettit, R.Daly, M.Cooper, J.Cornish, M.Forwood, E.Duncan
2019 – 21	N. Sims	M. Forwood	P. Anderson	N. Pavlos	A. Pettit, R. Davey, M. Cooper, J. Cornish, G. Duque, P. Croucher
2021 - 22	M. Forwood	M.Cooper	D.Coates	R. Davey	M. Cantley, C. Chiang, D. Coates, J. Lewis, M. McDonald, N. Sims
2022 - 23	M. Forwood	M.Cooper	D.Coates	R. Davey	Dr Melissa Cantley, A/Prof Cherie Chiang, A/Prof Dawn Coates, A/Prof Josh Lewis & Dr Michelle McDonald

## SPONSORS & AWARDS OF THE AUSTRALIAN & NEW ZEALAND BONE & MINERAL SOCIETY

### ROGER MELICK YOUNG INVESTIGATOR AWARD



This award is presented to commemorate the contribution of Dr Roger Aziz Melick to endocrinology and student education. Roger Melick died in November 1986 after a long battle with cancer. He trained in endocrinology with Fuller Albright, in Boston, and joined The Royal Melbourne Hospital as the third member of the foundation Department of Medicine. He was appointed Dean of the Clinical School in April 1979 and he was forced to retire because of his illness during 1986. Roger Melick was particularly known for his kindness, consideration and empathy for both patients and students. The prize is awarded annually to young members of the Society working towards a higher degree (including FRACP).

1996	Vicky Kartsogiannis	2005	James Doecke		Irina Kulina
1997	Linda Crofts	2006	Yosuke Kawasaki	2015	Niloufar Ansari
1998	Janelle Barry	2007	Stella Foley	2016	Christina Vrahnas
1999	Liza-Jane Raggatt		Garry Williams	2017	Mahmoud Bakr
2000	Sandra Iuliano-Burns	2008	Jonathan Gooi	2018	Jun Li
	Nathan Pavlos	2009	Nicola Lee	2019	Amy Harding
2001	David Good	2010	Irene Zinonos	2020	James Smith
2002	Kun Zhu	2011	Chiaming Fan	2021	Ruby Oberin
2003	Agatha Labrinidis	2012	Farzin Takyar	2022	Kaitlyn Flynn
	Xiaofang Wang		Audrey Chan	2023	Christal Au-Yeung
2004	Susan Allison	2013	Asiri Wijenayaka	2024	Lucy Collins
	Kirk Ho Man Yip	2014	Hua Ying		

## CHRISTOPHER AND MARGIE NORDIN YOUNG INVESTIGATOR POSTER AWARD



This Award is named in honour of the outstanding and major clinical investigations into disorders of bone and mineral metabolism made by Professor Christopher Nordin and his contributions to the ANZBMS. Professor B.E Christopher Nordin was a senior specialist at the Institute of Medical and Veterinary Science in Adelaide, and the man credited with drawing the medical community's attention back to the link between calcium deficiency and osteoporosis (brittle bones).

1997	Anne Nelson	2006	Andrew Hattam	Scott Youlten – Basic	
	Hidenori Murata		Estabelle Ang	2016	Audrey Chan
1998	Marianne Holzherr	2007	Taksum Cheng	2017	Scott Youlten
1999	Tanya Uebergang	2008	Hasnawati Saleh	2018	Alexander Rodriguez
2000	Josef Kaplan	2009	Ee-Cheng Khor	2019	Amy Ribet
2001	Rebecca Jackson	2010	Kylie Alexander	2020	Ruby Oberin
2002	Nathan Pavlos	2011	Shek Man Chim	2021	Amy Ribet
2003	Nicole Walsh	2012	Alvin Ng	2022	Selwin Gabriel Samuel
	Rouha Granfar		Marie-Luise Wille	2023	Krisel De Dios
2004	Laura Gregory	2013	Yu Wen Su	2024	Micaela Quinn
	Mark Bolland	2014	Masato Koike		
2005	Mark Bolland	2015	Dzenita Muratovic –		
	Catherine Wang		Clinical,		

## CHRISTINE AND T JACK MARTIN RESEARCH TRAVEL GRANT



This grant is offered by the ANZBMS in memory of Christine Martin and to honour the outstanding and major scientific contributions of Professor T Jack Martin to bone and mineral research and his contributions to associates and trainees in teaching, research, and administration.

2002	Catherine Middleton-Hardie	2010	Garry Williams	2019	Sabashini Ramchand
2003	Vicky Kartsogiannis	2011	Julie Quach	2020	*Not Awarded
2004	Kerrie Sanders	2012	Ashika Chhana	2021	*Not Awarded
2005	Susan Allison	2013	Yohann Bala	2022	Ahmed Al Saedi
2006	Mark Forwood	2014	Michelle McDonald		Niloufar Ansari
2007	Brya Matthews	2015	Christina Vrahnas		Martha Blank
2008	Roger Zebaze	2016	Audrey Chan		Pholpat Durongbahn
2009	Bich Tran	2017	Alexander Rodriguez	2023	Lieke Scheepers
		2018	Thao Ho-Le	2024	Haniyeh Hemmatian

## ANZBMS AND BONE HEALTH FOUNDATION AWARDS



Established in 1991, The Bone Growth Foundation Inc. trading as the Bone Health Foundation (BHF/Foundation) is a not-for-profit organisation that raises money for research and education into bone health and musculoskeletal conditions that affect Australians of all ages. The Foundation receives no government funding and relies solely on support from public and private individuals and organisations. The Australian and New Zealand bone and mineral society represent a research community

that has a proven track record of producing internationally competitive research outcomes which have a meaningful impact on individuals with poor bone health. The bone and mineral research sector is currently experiencing unprecedented challenges and historic low funding rates in major and international funding schemes. The ANZBMS and BHF have aligned purposes to enable rigorous research, advocacy and education focused on reducing the burden of bone disease. Together they are committed to ensuring this track record of excellence and impact, continues and thrives in the current climate of complex national funding conditions.

#### **ANZBMS Bone Health Foundation Grant-In-Aid**

2025 - Yinghong Zhou

#### **ANZBMS BHF Interdisciplinary Collaborative Grant**

2024 - Jessica Sandy

#### **ANZBMS Bone Health Foundation Health Innovation grant**

2024 - Marc Sim

#### **ANZBMS Bone Health Foundation Grant**

2023 - Jiao Jiao Li, Kathryn Stok

2022 - Sandra Iuliano, Nathan Pavlos

2021- Michelle McDonald, Fran Milat

#### **ANZBMS OUTSTANDING ABSTRACT AWARD**

The Council of ANZBMS wishes to recognise the high standard of bone and mineral research presented at the Annual Scientific Meeting. The Program Organising Committee will award a prize to the basic and clinical abstracts receiving the highest scores.

2003	Rob Will, Amanda Devine	Brennan, Jasreen Kular,	2017	Victoria D Leitch, Emma M
2004	Roger Zebaze	Markus Seibel		Wade, Michelle M
2004	Christine Rodda	2011		McDonald, Ego Seeman
2005	Markus Seibel, Julian Quinn	2012		Ian Reid, Nathan Pavlos
2006	Yosuke Kawasaki, Julie Kuliwaba, Stella Foley, Dana Bliuc, Jonathan Gooi, Hugh Zhang	2013		2018 Kai Chen, Robin Daly
2007	Colin Dunstan, Richard Prince, Maria Chiu, Natalie Sims, Paul Baldock, Ian Parkinson, Hong Zhou	2014		2019 Sandra Iuliano, Peter Ebeling, Audrey Chan, Victoria Leitch, Tsuyoshi Isojima
2008	Robert Kalak, Andrew Grey	2015		2020 Dana Bliuc, Ryan Chai, Alexander Corr, Albert Kim, Alexander Rodriguez
2009	Vicky Kartsogiannis, Nguyen Nguyen	2016		2021 Charles Inderjeeth, Michael J Rogers, Minghao Zheng, Brya Matthews, John Eisman
2010	Markus Seibel, Emma Walker, Iris Wong, Sarah			2022 Varun Venkatesh, Benjamin Mullin, Sandra Iuliano, Charles Inderjeeth
				2023 Kaitlyn A Flynn, Mike Lin

#### **ANZBMS CLINICAL RESEARCH EXCELLENCE AWARD**

This award is offered to recognise and support clinicians in or within 10 years of postgraduate training who are contributing to clinical research in the field of bone-related disorder.

2012	Belal Khan	2013	Syndia Lazarus		
2014	Masakazu Kogawa	2016	Thack Tran	2018	Jasna Aleksova
2015	Hanh Nguyen	2017	Weiwen Chen	2019	Alexander Rodriguez



## ANZBMS KAYE IBBERTSON AWARD FOR BONE AND MINERAL MEDICINE



This Award is named in honour of the outstanding career and major investigations into skeletal disorders made by Professor Kaye Ibbertson, and his contributions to the ANZBMS.

2005	Roger Zebaze	2015	Joshua Lewis, Rachelle Johnson
2006	Julie Pasco	2016	Michelle McDonald
2007	Tania Winzenberg	2017	Feitong Wu
2008	Paul Baldock	2018	Dawn Aitken
2009	Mark Bolland	2019	Fran Milat
2010	Kun Zhu	2020	David Scott
2011	Susannah O'Sullivan	2021	John Kemp
2012	Emma Duncan	2022	Natalie Wee
2013	Tara Brennan-Speranza	2023	Kai Chen
2014	Nicole Yu	2024	Lena Batoon, Yinghong Zhou

## SOL POSEN RESEARCH AWARD



This Award is named in honour of Professor Sol Posen who was one of the pioneers in the field of bone and mineral endocrinology in this country. Sol Posen's contributions span the range from basic biochemistry – his citation classic in Clinical Chemistry described the first means of distinguishing alkaline phosphatase of bone origin – to clinical studies in metabolic bone disease, including Paget's disease, osteoporosis, hyperparathyroidism and tumour-induced osteomalacia. He attended meetings and journal clubs, where his presence was marked, as ever, by his propensity to ask incisive questions.

2006	Nathan Pavlos	2013	Farzin M Takyar	2020	Jungie Gao
2007	Aaron McDonald	2014	Heath McGowan	2021	Niloufar Ansar
2008	Haotian Feng	2015	Dana Bliuc	2022	Kai Chen
2009	Ming-Kang Chang	2016	Paul Lee	2023	Varun Vankatesh
2010	Tak Sum Cheng	2017	Thao P. Ho-Le	2024	Eugenie MacFarlane
2011	Kylie Alexander	2018	Nicola Lee		Thach Tran
2012	Julie Quach	2019	Kai Chen		

## PHILIP SAMBROOK AWARD

The Professor Philip Sambrook Award is presented annually to an outstanding early career researcher to honour the major clinical and scientific contributions by Professor Philip Sambrook to the field of rheumatology and osteoporosis. Successful applicants must be passionate about bone research, results driven and committed to giving back to the community.



2012	Gustavo Duque	2019	Sabashini Ramchand
2013	Emma Duncan	2020	*Not Awarded
2014	Kirtan Ganda	2021	*Not Awarded
2015	Sharon Brennan-Olsen	2022	Natalie Hyde
2016	Jinwen Tu	2023	Kai Chen
2017	Jansa Aleksova	2024	Eugenie MacFarlane
2018	Feitong Wu		

## ANZBMS INTERNATIONAL TRAVEL AWARD

This award is offered by the ANZBMS to support travel to attend the IBMS Herbert Fleisch Workshop. The objective of this workshop is to provide a Gordon-conference style forum for students, post-docs and early stage principal investigators to present work in progress, discuss thoroughly and network with peers, and get constructive feedback from experienced senior scientists.

2014	Tara Brennan-Speranza, Ashika Channa, Christina, Vrahnas	2015	Campbell Macgregor, Megan Thomas, Scott Youlten	2022	Lena Batoon Ye Cao Annohya Gandham
		2018	Babtunde Ayodele, Dzenita Muratovic		

## ANZBMS CAREER ACHIEVEMENT AWARD

This esteem award recognises outstanding and major scientific or clinical contributions, and excellence in teaching and service to and within the bone and mineral field. The award will be widely publicised and presented annually during the society's Annual Scientific Meeting. The awardee will receive free registration to the Annual Scientific Meeting and invitations to the annual and the president's dinner the year the award is received.

2014	Jillian Cornish, Ego Seeman	2018	John Eisman	2022	Rebecca Mason
2015	Howard Morris	2019	Ian Reid	2023	Natalie Sim
2016	Jack Martin	2021	David Findlay		

## ANZBMS GAP FELLOWSHIP

In recent years, funding for mid-career researchers has become increasingly difficult to obtain, jeopardising the future career of many of our colleagues in bone and mineral research. The ANZBMS has therefore created a new Fellowship Award with the intention to bridge shortfalls in salary funding for outstanding mid-career scientists.

2016	Allison Pettit	2017	Nicki Lee Rachel Davey	2018	Dana Bliuc
------	----------------	------	---------------------------	------	------------

## ANZBMS HIGHEST RATED STUDENT ABSTRACT AWARD

The prize, of a single free registration, will be awarded to the student first author of the abstract that receives the highest score from the scoring committee.

2017	Junjie Gao	2020	Lena Batoon	2023	Kavindi Weerasinghe
2018	Marija Simic	2021	Shoichiro Tani	2024	Natalie Koh
2019	Kotaro Tanimoto	2022	Tian Nie		

## ANZBMS LIFE MEMBERS

Professor Henry Kaye Ibbertson  
(deceased)

Associate Professor Jane Moseley

Professor B.E.C Nordin (deceased)

Dr Solomon Posen (deceased)

Professor Thomas J. Martin

Dr Donald Gutteridge

Dr Ailsa Goulding

Associate Professor Michael

Hooper

Professor John Eisman

Professor Ego Seeman

Professor Jillian Cornish

Professor Rebecca Mason

Professor Ian Reid

Professor David Findlay

## BRIDGING OVERSEAS NETWORKING AND EXCHANGE (B.O.N.E) PROGRAM

The Bridging Overseas Networking and Exchange (B.O.N.E) Program is an ANZBMS Early Career Investigator Committee (ECIC) initiative, established in 2018, to address the limited opportunity and funds for invited presentations for early career investigators (ECI) in the musculoskeletal field. This program will boost ECIs track records, increase their exposure, provide travel support, and facilitate international networking and collaboration – together enabling more competitive track records for future funding opportunities.

2019 Michelle McDonald (attended JSBMR)

2020 Kylie Alexander (attended JSBMR)

2022 Timo Damm (ASBMR), Monika Frysz (BRS), Marc Sim (attended BRS), Dima A Alajilouni (attended ASBMR)

2023 Michaela Tencerova (ECTS), Lama Alabdulaaly (ASBMR), Dzenita Muratovic (attended ECTS), Ngoc Josie Huynh (attended ASBMR)

2024 Katharina Jähn-Rickert (ECTS), Andrea Cowan (ASBMR), Christian Girgis (attended ECTS), Ben Kirk (attended ASBMR)

2025 Kai Chen, ANZBMS (attended ASBMR,) Matthias Walle, ASBMR (attended ANZBMS), Melissa Cantley, ANZBMS (attended JSBMR), Mikihiro Hayashi, JSBMR (attended ANZBMS)

## CLINICAL CASES IN METABOLIC BONE DISEASE SEMINAR AWARD

The Clinical Cases in Metabolic Bone Disease Seminar was established in 2018 to encourage clinical interest in metabolic bone research in junior clinicians. This seminar provides an opportunity for physician trainees to present their case and literature review to a national scientific audience. It is anticipated that each case will spark lively discussion regarding complex areas of metabolic bone disease, engaging both clinicians and scientists. The clinical cases session aims to foster interest in the bone field amongst advanced trainees and senior clinicians and hopes to engage them into the wider clinician-researcher network.

2018 Kate Haigh / Alicia Jones

2019 Genevieve Calder

2022 Lucy Collins

2023 Amanda Ji

2024 Sarah Dixon



Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company, contributing to human health and well-being worldwide through innovative drug discovery and global commercialization.

Driven by state-of-the-art antibody technologies and hematopoietic stem cell gene therapy, our global business is focused on bone & mineral, intractable haematological diseases/haemato-oncology, and rare diseases.

**Kyowa Kirin is proud to be a Major Sponsor  
of the 2025 ANZBMS ASM.**

**Visit us at the stand to discuss the latest developments in the  
management of X-linked hypophosphataemia (XLH).**



Kyowa Kirin Australia Pty Ltd,  
68 York Street, Sydney, NSW 2000, Australia.  
[enquiry.kkau@kyowakirin.com](mailto:enquiry.kkau@kyowakirin.com)  
[www.kyowakirin.com/australia](http://www.kyowakirin.com/australia)

AU-NP-25-00007

---

## DELEGATE INFORMATION


---

### VENUE

Cairns Convention Centre  
Corner Wharf and Sheridan Streets  
Cairns, QLD 4870  
Phone: +61 7 4042 4200

### CAIRNS CONVENTION CENTRE MEZZANINE LEVEL

---



### THE REGISTRATION DESK

The registration desk is located on the Mezzanine Level, located on the second level of the Cairns Convention Centre. Any enquiries can be directed to ASN staff located at the registration desk except those regarding accommodation which should be dealt directly with your hotel.

The registration desk office hours are:

Sunday 9 November	11:00AM – 6:30PM
Monday 10 November	7:30AM – 6:30PM
Tuesday 11 November	7:00AM – 7:00PM
Wednesday 12 November	8:30AM – 12:30PM

### LOADING YOUR ORAL PRESENTATION AT THE CONFERENCE

Oral presenters should bring their talk on a USB, saved in a format for display on a PC within Penary 1 & 2 (i.e. PowerPoint). You will need to load your presentation directly into Plenary 1 & 2 located on the upper level of the Cairns Convention Centre. A technician will be on hand to assist with any transfer / loading issues and to help you check your presentation. Please note there are no Macintosh computers in the presentation room – please format your USB drives appropriately (FAT32).



## REGISTRATION

Conference delegates receive the following services as part of their registration:

- Access to the sessions of your choice
- Conference E-book
- Use of the Conference App
- Morning and/or afternoon tea for the days of nominated attendance
- Lunches on the days of nominated attendance
- Welcome Function (Sunday 9 November)

## NAME TAGS

Delegates are required to wear their name tags to all scientific and catered sessions. Delegates should note that on the back of their name badges there are symbols representing the specific function tickets they have purchased.

## POSTER VIEWING

Delegates with posters can find the correct position for their poster by locating the appropriate abstract number on the back of their name badge, which will be matched against the number on the display panels.

The Plenary posters are displayed in at the back of Plenary 1 & 2, located on the first floor and can be placed on the boards for the duration.

## POSTER SESSIONS

Due to space limitations at the Cairns Convention Centre, we will have two poster sessions held within the Trinity Mezzanine and each session will have an allocated period of time to display your poster.

**Poster Session 1** - Odd Numbers - Monday 10 November from 5:00pm - 6:00pm

**Poster Session 2** - Even Numbers & Nordin Viewing - Tuesday 11 November from 10:30am - 11:30am

We encourage you to be at your poster during your allocated poster session to answer questions and engage with fellow delegates. There is a 30-minute poster tour prior to each poster session and we encourage you to attend.

## POSTER DISPLAY

Poster Session 1:

SET-UP: You can hang your poster from 1:00pm onwards on Sunday 9 November

TAKEDOWN: Your poster must be removed by the end of programming on Monday 10 November

Poster Session 2:

SET-UP: You can hang your poster from 8:00am onwards on Tuesday 11 November

TAKE-DOWN: Your poster must be removed by 11:00am on Wednesday 12 November

## RECORDING OF SESSIONS AT ANZBMS 2025

All sessions within Plenary 1 & 2 will be recorded at the conference. If you do not wish to have your presentation recorded, please advise ASN Staff at the registration desk.

## LECTURE ROOMS

All mainstream lectures for the meeting will run within Plenary 1 & 2 at the Cairns Convention Centre. The Arrotex Lunchtime Symposium is being held in Meeting Room 9.

## PARENTS ROOM

The parent's room can be found beside room M14 on the Mezzanine Level, beside the Plenary Rooms. Please refer to the floorplan above or ask ASN staff at the Registration Desk for directions.

## SOCIAL FUNCTIONS

### Welcome Function

**Date:** Sunday 9 November 2025

**Time:** 6:00PM – 7:30PM

**Price:** Complimentary with Full Conference Registration

**Location:** Trinity Mezzanine, Cairns Convention Centre

**Additional ticket:** \$65.00

*\*Additional tickets for partners can be purchased in advance or at the registration desk.*

### ECIC - 'Bones & Brews' Networking Dinner

**Date:** Sunday 9 November 2025

**Time:** 7:30PM – 10:00PM

**Location:** Hemingways Brewery

**Cost:** \$50.00

**Student/ECR cost:** \$25.00

*\*This is a ticketed function; tickets can be purchased in advance or at the registration desk*

### Clinical Cases in Metabolic Diseases Seminar

**Date:** Monday 10 November 2025

**Time:** 6:00PM – 8:00PM

**Price:** \$30 (Trainee or Student), \$60 (others)

**Location:** Meeting Room 9, Dinner and drinks provided

### DXA/REM's Breakfast

**Date:** Tuesday 11 November 2025

**Time:** 7:00AM – 8:30AM

**Price:** Free to all attendees

**Location:** Plenary 1 & 2. Breakfast provided.

### Arrotex Lunchtime Symposium

**Date:** Monday 10 November 2025

**Time:** 1:00PM – 2:00PM

**Price:** Complimentary with Full Conference Registration

**Location:** Meeting Room 9

### ANZBMS Conference Dinner

**Date:** Tuesday 11 November 2025

**Time:** 6:20PM – 11:00PM

**Price:** \$75 (Student/ECR), \$130 (Other) Additional ticket \$140

**Location:** Rainforestation

*\*This is a ticketed function; tickets can be purchased in advance or at the registration desk. Buses will transport people to the venue and will depart the Cairns Convention Centre at 6.20PM and will be available to pick up guests from Rainforestation back to Hilton Double Tree and Cairns Lagoon bus bays at 9:30pm with the last coach departing at 11:00PM.*

## DIETARY REQUIREMENTS

If you requested a special meal, please make yourself known to the venue staff and advise your name and special request.

## SMOKING

Smoking and vaping are not permitted in the venue. There are designated smoking areas outside the entrances to the Convention Centre.

## MOBILE PHONES

Please ensure your mobile phone is turned off or on silent during any session you attend.

## INSURANCE

The hosts and organisers are not responsible for personal accidents, any travel costs, or the loss of private property and will not be liable for any claims. Delegates requiring insurance should make their own arrangements.

## DISCLAIMER

The hosts, organisers and participating societies are not responsible for, or represented by, the opinions expressed by participants in either the sessions or their written abstracts.

## WI-FI INTERNET

The Cairns Convention Centre provides complimentary Wi-Fi:

ANZBMS Annual Scientific Meeting Delegate Booklet 2025

Digital Delegate Handbook sponsored by:



Network: CCC Convention  
Password: Cairns2025

#### **CONFERENCE APP**

The 2025 Conference App is available now. Please see below for details on how to access.




# CONFERENCE APP 2025

## DOWNLOAD

### 1. DOWNLOAD THE CONFERENCE APP

Through the App Store or Google Play download **Exposcan Launcher**.



Exposcan Launcher  
[exposcan.net.au](http://exposcan.net.au)

### 2. ENTER YOUR EVENT CODE

Using event code **ANZBMS** (not case sensitive).

### 3. LOGIN

You will need to log into the app to be able to view the attendee list and interact within the app. Visit the 'Log In' icon in the app, enter the email you registered with and temporary password **ANZBMS** (case sensitive). You will then be prompted to create your own personal password and must be at least 6 characters in length.

### 4. EXPORT YOUR NOTES

At any stage throughout the Conference you are able to make and export notes within the program. To export notes, visit the 'Log In' icon in the app and select export notes. **NB: If you delete the app on your device before exporting your notes, the notes will be deleted.**

---

## INVITED PLENARY SPEAKERS

---

**Prof Morten Frost**

*University of Southern Denmark, Denmark*

**A/Prof Marc Wein**

*Massachusetts General Hospital, USA*

**Prof Gert Carmeliet**

*University in Leuven, Belgium*

---

## INVITED SYMPOSIUM SPEAKERS

---

**A/Prof Dawn Coates**

*University of Otago, Dunedin, New Zealand*

**Dr John Kemp**

*Mater Research, Brisbane, Australia*

**Dr Cassandra Smith**

*Edith Cowan University, Melbourne, Australia*

**Prof Rachel Davey**

*The University of Melbourne, Australia*

**A/Prof Nicholas Pocock**

*St Vincent's Hospital, Australia*

**Professor Bronwyn Stuckey AM**

*Sir Charles Gairdner Hospital, Australia*

**Prof Emma Duncan**

*King's College, London*

**Dr Lieke Scheepers**

*Menzies Institute for Medical Research, Australia*

**Dr Matthias Walle**

*University of Calgary, Canada*

**Dr Mikihiro Hayashi**

*Institute of Science Tokyo, Japan*

**Dr John Schousboe**

*HealthPartners Institute, USA*

**Dr Sandra Iuliano**

*The University of Melbourne, Australia*

**Dr Marc Sim**

*Nutrition and Health Innovation Research Institute (NHIRI), Australia*



## **Sunday 9th November 2025**

### **Green Island Discovery Tour**

Delegates to make their own way to/from terminal - 10 min walk from most hotels.

**Depart:** Green Island DISCOVERY from Reef Fleet Terminal Cairns. (1 Spence Street in Cairns)

**Departure Time:** 8.30am

**Return Time:** 2.30pm

### **Registration desk opens**

11:00AM - 6:30PM

Registration M15

### **ANZBMS Presidents Function**

12:00PM - 1:00PM

Meeting Room 4 Foyer

### **ANZBMS Council Meeting**

1:30PM - 3:15PM

Meeting Room 4

### **Science at Speed Networking Session - Bridging the gap between EMCR's and Seniors**

2:00PM - 3:00PM

Plenary Room 1 & 2

### **ANZBMS Symposium - Spine Imaging, Aortic Calcification and Bone Health / Exercise in Bone Health**

3:30PM - 4:30PM

Plenary Room 1 & 2

*Chairs: Amy Harding & Itamar Levinger*

3:30 PM

**John Schousboe**

Spine Imaging, Aortic Calcification, and Bone Health

*abs# 1*

4:00 PM

**Cassandra Smith**

Strong Bones and Healthy Hearts: Common Pathways, Shared Risk factors, and the role of Movement in Healthy Aging

*abs# 2*

### **ANZBMS Debate: "Nutritional therapy is better than pharmacotherapy for prevention of bone loss in the older adult"**

4:30PM - 5:30PM

Plenary Room 1 & 2

*Chair: Craig Munns*

**FOR:**

**Dr Sandra Iuliano and Dr Marc Sim**

**AGAINST:**

**Prof Emma Duncan and Prof Robert Blank**

### **ANZBMS Plenary Posters**

5:30PM - 6:00PM

Plenary Room 1 & 2

#### **Dennis Chan**

Determinants of REMS Femoral Neck Fragility Score

*abs# 111*

#### **Anthony Dosseto**

Calcium Isotope Markers (CIM): A Novel Tool for Early Detection and Monitoring of Osteoporosis

*abs# 112*

#### **Pholpat Durongbhan**

Decoupling calcified cartilage from cortical bone reveals distinct mineralisation patterns in an osteoarthritis mouse model

*abs# 113*

**Abadi Gebre**

Automated abdominal aortic calcification and trabecular bone score independently predict incident fracture during routine osteoporosis screening *abs# 114*

**Miki Maemura**

Regulation of Bone and Cartilage Metabolism by Supersulfides and Their Therapeutic Potential *abs# 115*

**Luisa Rosi**

Bone health in heart transplantation: a Melbourne perspective revealed a higher rate of post-transplant fractures in females which occurred earlier than in males despite antiresorptive therapy and preserving bone density those who received it. *abs# 116*

**Hideaki Sabe**

In Vivo Profiling of Osteoclast Gene Expression Using a Novel Binary Cre - RiboTag System *abs# 117*

**Kenta Sawamura**

Meclozine and growth hormone ameliorate bone length and quality in experimental models of achondroplasia *abs# 118*

**Angela Sheu**

3D Shaper in Monitoring Bone Loss in Lung Transplant Patients *abs# 119*

**Kun (Kathy) Zhu**

DXA-measured visceral adipose tissue and accelerated biological ageing in middle-aged adults *abs# 120*

**ANZBMS Welcome Function**

6:00PM - 7:30PM

Trinity Mezzanine

**Bones and Brews**

7:30PM - 10:00PM

Hemingways Brewery, 4 Wharf Street, Cairns

**Monday 10th November 2025****Registration desk opens**

7:30AM - 6:30PM

Registration M15

**ANZBMS Symposium - Diabetes and Bone Health**

8:30AM - 9:15AM

Plenary Room 1 & 2

*Chair: Angela Sheu & Ryan Chai*

8:30 AM

**Morten Frost**

Diabetes and its effect on bone health

*abs# 3*

**ANZBMS Outstanding Abstracts**

9:15AM - 10:00AM

Plenary Room 1 & 2

*Chair: Angela Sheu & Ryan Chai*

9:15 AM

**Mike Lin**

Bisphosphonates or Denosumab after Fracture? Real-World Evidence from a Target Trial Emulation in Multimorbid Adults

*abs# 4*

9:35 AM

**Xiaojun X.C. Chen**

Oxr1-Dependent Autophagy Drives Osteoclastogenesis by Mitigating ROS-Induced Mitochondrial Damage

*abs# 5*

9:55 AM	<b>Julian Chu</b> Tissue-specific knockdown of the vitamin D receptor in mice via muscle- and bone-targeted rAAV vectors <i>abs# 6</i>	
<b>Morning Tea &amp; Meet the Expert Session</b>		
10:00AM - 10:45AM	'Meet the Expert' – Professor Morten Frost	Trinity Mezzanine
<b>ANZBMS Roger Melick Young Investigator Award Symposium</b>		
10:45AM - 1:00PM		Plenary Room 1 & 2
<i>Chair: Christa Maes &amp; Albert Kim</i>		
10:45 AM	<b>Johanna Besold</b> MMP-9 has a sex-specific role in the anabolic effects of intermittent parathyroid hormone in trabecular bone <i>abs# 7</i>	
11:00 AM	<b>Mary Louise Fac</b> Women produce bone with less carbonate substitution than men, and exhibit a sex-specific difference in collagen deposition with age <i>abs# 8</i>	
11:15 AM	<b>Han Liu</b> <i>In vivo</i> micro-computed tomography imaging allows tracking of bone remodelling activity with progression of osteoarthritis <i>abs# 9</i>	
11:30 AM	<b>Krisel De Dios</b> Genome wide association analysis of volumetric bone mineral density phenotypes: the Vietnam Osteoporosis Study <i>abs# 10</i>	
11:45 AM	<b>Melkamu Tamir Hunegnaw</b> Effects of a Smartphone App–Delivered Exercise Intervention on Musculoskeletal Health in Older Adults with Sarcopenic Obesity Undergoing Caloric Restriction: A 6-Month Randomised Controlled Trial <i>abs# 11</i>	
12:00 PM	<b>Mawson Wang</b> Determinants of refracture and mortality in patients managed by a secondary fracture prevention program: insights from over a decade of follow-up <i>abs# 12</i>	
12:15 PM	<b>Dennis Chan</b> Influence of Non-Skeletal Input Parameters on REMS BMD Assessment <i>abs# 13</i>	
12:30 PM	<b>Saroj Sahoo</b> Identification of novel <i>GCM2</i> and <i>AIRE</i> mutations in sporadic and seemingly idiopathic hypoparathyroidism by whole-exome sequencing <i>abs# 14</i>	
<b>Lunch</b>		
1:00PM - 2:00PM		Trinity Mezzanine
<b>Arrotex lunchtime Symposium</b>		
1:00PM - 2:00PM		Meeting Room 9
<b>Presenter:</b> A/Prof Cherie Chiang		
<b>Title:</b> Long-Term Denosumab Use: Translating Evidence into Everyday Care		
<b>ANZBMS Symposium - OMICS</b>		
2:00PM - 2:30PM		Plenary Room 1 & 2
<i>Chair: Emma Duncan &amp; Dougall Norris</i>		
2:00 PM	<b>John Kemp</b> Using multi-omics to discover new molecular determinants of skeletal health and disease. <i>abs# 15</i>	

## ANZBMS selected oral abstracts

2:30PM - 3:30PM

Plenary Room 1 & 2

*Chair: Emma Duncan & Dougall Norris*

- 2:30 PM **Ryan Chai**  
Romosozumab for patients with multiple myeloma with skeletal events on zoledronic acid  
*abs# 16*
- 2:45 PM **Melissa D Cantley**  
Circulating Tumour and Bone Marrow Microenvironment Derived Factors Distinguish MGUS from Multiple Myeloma  
*abs# 17*
- 3:00 PM **Roger Zebaze**  
Disorganization of Bone Components in Metabolic and Genetic Bone Disorders such as Hypophosphatasia: Emerging Insights into Pathogenesis and Clinical Assessment  
*abs# 18*
- 3:15 PM **Kai Chen**  
Spatial Mapping of Glucose-to-Fat Conversion in Bone Marrow: Implications for Therapeutic Targeting  
*abs# 19*
- 3:30 PM **Huy Nguyen**  
Accurate Identification of High-risk Individuals for Imminent Subsequent Fractures: A Deep Learning Approach using Administrative Data  
*abs# 20*

## Afternoon Tea & Meet the Expert Session

3:30PM - 4:00PM

Trinity Mezzanine

'Meet the Expert' – Professor Emma Duncan

## Dental Tissue Regeneration

4:00PM - 4:30PM

Plenary Room 1 & 2

*Chairs: Morten Frost & Ghsaq Alhamdani*

- 4:00 PM **Dawn E Coates**  
Bioengineering of novel bone-grafting materials for oral applications  
*abs# 21*

## ANZBMS Poster Tour 1 (5 basic & 5 clinical)

4:30PM - 5:00PM

Trinity Mezzanine

- 4:30 PM **Kara B Anderson**  
Associations between "peak bone mass" and later life bone density: Data from the Geelong Osteoporosis Study  
*abs# 121*
- 4:33 PM **Agnieszka Arthur**  
Concomitant spinal cord injury and traumatic brain injury impact bone remodelling, understanding the molecular changes through proteomic analysis.  
*abs# 122*
- 4:36 PM **Melkamu Tamir Hunegnaw**  
Effects of A Digital Voice Assistant-Delivered Osteoporosis Self-Management Program on Diet in Postmenopausal Women with Osteoporosis: A 12-Month Randomised Controlled Trial  
*abs# 123*
- 4:39 PM **Benjamin H Mullin**  
Genome-wide association study meta-analysis identifies association of a locus containing the vitamin D 24-hydroxylase gene (CYP24A1) with bone mineral density  
*abs# 124*
- 4:42 PM **Yukiko Noguchi**  
Hard tissue-forming ability of alpha-smooth muscle actin-positive cells in dental pulp  
*abs# 125*
- 4:45 PM **Ken Qu**  
Making the first fracture the last fracture Examining the efficacy of the Westmead Hospital Fracture Liaison Service in reducing re-fractures over 3 years  
*abs# 126*

4:48 PM **David Scott**

Feasibility, safety and efficacy of OsteoStrong® in postmenopausal women with low bone mineral density *abs# 127*

4:51 PM **Nick Tran**

"Skeletal Age" for cumulative impact of cigarette smoking on post-fracture mortality *abs# 128*

4:54 PM **Yuandan Zhang**

Genetic differences between abdominal aortic and coronary artery calcification and implications for vascular disease and adverse health outcomes *abs# 129*

4:57 PM **Yinghong Zhou**

Melatonin Promotes Osteogenesis but Activates TLR4-Mediated Osteoclastogenesis in a Dose-Dependent Manner *abs# 130*

### **ANZBMS Poster Session 1 - Odd numbers**

5:00PM - 6:00PM Trinity Mezzanine

**Kara B Anderson**

Fracture rates decline during COVID-19 lockdowns *abs# 141*

**Daniel Bennett**

Fracture Prophylaxis for Adult Lung Transplant Recipients: a clinical audit of fracture risk identification and prevention *abs# 143*

**Nathan Cheuk**

Hypercalcaemia in a tiger man *abs# 145*

**Hannah Cunningham**

Challenges in management of low bone density in a young man with malabsorption and recurrent iron infusions *abs# 147*

**Zoe Gavey**

Rock solid but fragile: a case of autosomal dominant osteopetrosis *abs# 149*

**Ali Ghasem-Zadeh**

Patients With Chronic Kidney Disease Have Accelerated Microarchitectural Bone Deterioration *abs# 151*

**Amy T Harding**

What outcomes matter to people living with or at risk of minimal trauma fracture? Findings from the 'Measures that Matter' survey *abs# 153*

**Evelyn Hao**

Bone health screening in patients with type 2 diabetes mellitus - a single-centre retrospective audit *abs# 155*

**Natalie K Hyde**

The reliability of neonatal screening for developmental dysplasia of the hip in a regional service: How many cases are we not capturing? *abs# 157*

**Annabelle Kimmorley**

Running on empty: assessing the cost of low energy availability on female athlete bone health through quantitative ultrasound *abs# 159*

**Siehoon Lah**

Bone Mineral Density Changes After Liver Transplantation: Experience from A Tertiary Transplant Unit *abs# 161*

**Paul Lawton**

Giant Cells, Giant Questions: Denosumab Therapy in Central Giant Cell Granuloma *abs# 163*

**Sarina LIM**

Ten years clinical experience of bone health in aging transgender women from a single practice *abs# 165*

**Yosuke Mano**

The impact of metabolic syndrome on changes in trunk muscle cross-sectional area: a 10-year longitudinal study. *abs# 167*



**Anna Maria Markarian**

Profiling Tibial Cortical BMD Gradients: Associations with Body Composition in Childhood Cancer Survivors and Controls  
*abs# 169*

**Joel Olney**

Education of Junior Medical Officers Improves Identification and Accurate Coding of Osteoporotic Fractures  
*abs# 171*

**Lai-Ming Kathleen Pak**

Denosumab followed by romosozumab significantly improved bone density but did not prevent rebound vertebral fractures – A Case Report  
*abs# 173*

**Julie A Pasco**

Mood disorder and Bone Material Strength Index in women  
*abs# 175*

**5:00 PM Ahmed Al Saedi**

A novel role of CXXC Finger Protein1 in calvarias development and osteoblast differentiation  
*abs# 193*

**Dishan Samaranayake**

Beyond the jaw: teriparatide in the management of bilateral external auditory canal osteonecrosis  
*abs# 177*

**Angela Sheu**

DXA based 3-dimensional (3D) modelling technology to examine differential bone loss following heart transplantation  
*abs# 179*

**Andrea Sit**

Skeletons in the closet: Missed opportunities to institute osteoporosis therapy after minimal trauma fractures – a single-centre retrospective audit  
*abs# 181*

**David Tognarini**

Relationship Between REMS-Derived Fragility Score, Age and Bone Mineral Density in Australian Patients  
*abs# 183*

**Julia JT Tsolakis**

Beware the rebound when breaking up with denosumab  
*abs# 185*

**King Ho Wong**

Biannual Bone Bolstering Business - Insights from Following Up Continuation of Denosumab as Management of Clinical Osteoporosis at a Major Trauma Centre  
*abs# 187*

**Damian Wu**

Trabecular bone score in lung transplant recipients  
*abs# 189*

**Daheng Xia**

A Case of Bilateral External Auditory Canal Osteonecrosis and Novel Treatment with Teriparatide  
*abs# 191*

**ECIC Clinical Cases in Metabolic Bone Disease Seminar**

6:00PM - 8:00PM Meeting Room 9

**Arrival Drinks**

6:00PM - 6:15PM Meeting Room 9

**Clinical Cases 1 & 2**

6:15PM - 6:55PM Meeting Room 9

*Chairs: Amanda Ji, Sarah Dixon, Angela Sheu*

6:15 PM **Lai-Ming Kathleen Pak**  
 A heartbreaking case of hypocalcaemia  
*abs# 48*

6:35 PM **Huy H Do**  
 Diffuse osteosclerosis in a patient with systemic mastocytosis  
*abs# 49*

**Dinner & Networking**

6:55PM - 7:20PM Meeting Room 9

## Clinical Cases 3 & 4

7:20PM - 8:00PM

Meeting Room 9

*Chairs: Amanda Ji, Sarah Dixon, Angela Sheu*

7:20 PM

**Fiona Vaz**

When Hormones Meet Hypophosphatemia: the complex relationships of Iron, Phosphate, Periods, and Pregnancy in Autosomal Dominant Hypophosphataemic Rickets

*abs# 50*

7:40 PM

**Saroj Sahoo**

Phenotypic primary hyperparathyroidism cured after focused parathyroidectomy in a patient with familial hypocalciuric hypercalcaemia

*abs# 51*

## Tuesday 11th November 2025

### Registration Desk Opens

7:00AM - 7:00PM

Registration M15

### DXA/REM's Breakfast Workshop - "Alternative Modalities for Fracture Risk Assessment"

Plenary Room 1 & 2

7:00AM - 8:30AM

Breakfast from 7.00am - 7.30am

Session from 7.30am - 8.30am

Session Presenters:

- REMS: Patrick Baquir / Dennis Chan (20 Minutes)
- AI / opportunistic CT: Mawson Wang (15 - 20 Minutes )
- TBS: Nick Pocock 10min (if Time)

Followed by a 10 minute discussion

### ANZBMS Plenary Session

8:30AM - 9:00AM

Plenary Room 1 & 2

*Chairs: Kai Chen & Micaela Quinn*

8:30 AM

**Marc Wein**

Parathyroid hormone actions in bone and mineral metabolism

*abs# 22*

### Christopher and Margie Nordin Young Investigator Award

9:00AM - 10:00AM

Plenary Room 1 & 2

*Chairs: Kai Chen & Micaela Quinn*

9:00 AM

**Owen Taylor-Williams**

Cardiovascular and Infectious Diseases are Key Drivers of Mortality After Fracture in Rheumatoid Arthritis

*abs# 101*

9:06 AM

**Qiongxiang Lin**

A Robust SEM-BSE Workflow for Large-Field and High-Resolution Imaging of Skeletal Tissues

*abs# 102*

9:12 AM	<b>Lai-Ming Kathleen Pak</b> Influence of initial fracture site on subsequent fracture at an Australian tertiary health service <i>abs# 103</i>
9:18 AM	<b>Yang Sun</b> Lactoferrin acts synergistically with flucloxacillin against mature <i>Staphylococcus aureus</i> biofilm in vitro <i>abs# 104</i>
9:24 AM	<b>Phuong Dung Lam</b> Knowledge, attitudes and intentions towards osteoporosis and other health conditions among older Australians <i>abs# 105</i>
9:30 AM	<b>Hayley Neilsen-Burke</b> Investigation on the permeability of 3D printed zirconia bone implants <i>abs# 106</i>
9:36 AM	<b>Nick Tran</b> Reversible impact of cumulative cigarette smoking exposure and cessation on fragility fractures in older men <i>abs# 107</i>
9:42 AM	<b>Dinh Tan Nguyen</b> An AI-Agent for Personalized Time to Repeat Bone Mineral Density measurement <i>abs# 108</i>
9:48 AM	<b>Serena Chong</b> Bone health outcomes in patients transitioning off denosumab therapy <i>abs# 109</i>
9:54 AM	<b>Shejil Kumar</b> Disease burden and treatment patterns in adult patients with X-linked hypophosphataemia: results from an Australian clinician survey <i>abs# 110</i>

#### Morning Tea

10:00AM - 10:30AM Trinity Mezzanine

#### ANZBMS Poster Tour 2 (5 basic & 5 clinical)

10:00AM - 10:30AM Trinity Mezzanine

10:00 AM **Kara B Anderson**  
Incidence of vertebral fracture in a cohort of Australian women: Data from the Geelong Osteoporosis Study  
*abs# 131*

10:03 AM **Ghsaq Alhamdani**  
Collagen-based constructs for periodontal disease and bone regeneration  
*abs# 132*

10:06 AM **Mícheál Ó Breasail**  
Rural-urban differences in osteoporosis and sarcopenia prevalence among Gambian older adults: A pilot study  
*abs# 133*

10:09 AM **Cherie Chiang**  
Myeloma screen has poor yield as part of secondary osteoporosis screen  
*abs# 134*

10:12 AM **Terrence Diamond**  
Negative impact of pelvic radiotherapy on bone mineral density in women treated with gynaecological malignancies  
*abs# 135*

10:15 AM **Kaitlyn A Flynn**  
Evaluating the utility of zebrafish scales to model cellular and genetic determinants of human bone health  
*abs# 136*

10:18 AM **Annelies E Smit**  
Developing a preclinical model to distinguish inflammation- and glucocorticoid-driven bone loss in the context of arthritis  
*abs# 137*

10:21 AM **Tahnee Thatcher**  
Early Trabecular Bone Microarchitecture Deficits in a Female Mouse Model of Parkinson's Disease.  
*abs# 138*

10:24 AM **Owen Taylor-Williams**  
Revision Risk Following Primary Total Hip Arthroplasty in Australian Rheumatoid Arthritis Patients  
*abs# 139*

ANZBMS Annual Scientific Meeting Delegate Booklet 2025

25 | Page

Digital Delegate Handbook sponsored by:



10:27 AM **Shinji Yamada**

Prevalence and Incidence of Vertebral Fractures in Middle-aged and Older Working Men: A Cross-sectional and Longitudinal Study *abs# 140*

**ANZBMS Poster Session 2 - Even numbers & Nordin Poster Viewing**

10:30AM - 11:30AM

Trinity Mezzanine

**Kara B Anderson**

Advanced Paternal Age and Offspring Bone Health in Adulthood; Do Associations Reported in Childhood Persist?

*abs# 142*

**Kara Anderson**

Psychotropic medication use and bone loss in men

*abs# 144*

**Denekew Tenaw Anley**

Title: Menopause-related bone loss in women living with HIV: A systematic review

*abs# 146*

**Daisuke Arakawa**

[4-(Methylthio) phenylthio] methane bisphosphonate (MPMBP) prevents deterioration of bone microarchitecture, reduction of soleus muscle mass, and increase of visceral fat in elastase-induced emphysema mice *abs# 148*

**Sarah C Brennan**

Anabolic effects of romosozumab in an Australian context with notable prior anti-resorptive treatment *abs# 150*

**Dimitrios DC Cakouros**

The interplay between histone/DNA modifying enzymes and metabolites in regulating bone aging and metabolism

*abs# 152*

**Christopher Chan**

Systemic mastocytosis and osteoporosis - a clinical case and review of the literature

*abs# 154*

**Lai-Ming Kathleen Pak**

Unexplained Fragility Fractures and Elevated IgE: Two Cases Suggesting Hyper-IgE Syndrome and a Novel Adverse Reaction to Romosozumab *abs# 156*

**Jack Dalla Via**

Co-designing a digital health tool to support self-management of hypophosphatasia in adults

*abs# 158*

**Michael Fogarty**

B6 toxicity: an important hypocalcaemia mimic

*abs# 160*

**Kirtan Ganda**

Assessing Protocolisation of Hypophosphataemia Screening in High-Risk Patients Receiving Parenteral Iron *abs# 162*

**Natalie K Hyde**

Risk of fracture in adulthood is associated with childhood fracture history independent of bone mineral density in women: The Geelong Osteoporosis Study *abs# 164*

**Amanda Ji**

Multiple paragangliomas and osteoporosis in a patient with DNMT3A mutation: a new association

*abs# 166*

**Brintha Krishnamoorthi**

"Deadly double-trouble" – life-threatening hypocalcaemia following denosumab and parenteral iron administration *abs# 168*

**Siehoon Lah**

Laxative misuse resulting in hypercalcaemia with inappropriately normal parathyroid hormone levels and digital clubbing: A case series *abs# 170*

**Annabel Lee**

Challenges in managing hypercalcaemia in pregnancy: two case reports

*abs# 172*

**Anna Maria Markarian**

Zoledronic Acid in Pediatric Acute Lymphoblastic Leukemia Management: A Case Report of Region-Specific Bone Recovery *abs# 174*

**Renae Beardmore**

Out of the shadow: Transforming care for people living with hypophosphatasia

abs# 176

**Julie A Pasco**

Intrinsic capacity and sarcopenia: data from the Geelong Osteoporosis Study

abs# 178

**Charlotte Piesse**

A case of Gnathodiaphyseal Dysplasia/"High Bone Mass Osteogenesis Imperfecta" due to novel COL1A1 mutation

abs# 180

**Alexander Rodriguez**

A randomised controlled trial of vitamin D combined with exercise on arterial stiffness in vitamin D deficient, overweight/obese older adults

abs# 182

**Owen Taylor-Williams**

The Effect of Modern Pharmacotherapy on Bone Mineral Density in Rheumatoid Arthritis Patients

abs# 184

**Mina Toumas**

Congenital Hypogonadotropic Hypogonadism with FGFR1 mutation and progressive decline in bone mineral density.

abs# 186

**Aminu Suleiman**

Healthy Ageing Without Major Osteoporotic Fracture or Joint Replacement Surgery: A Time-Dependent Competing Risks Analysis Using Inverse Probability Weighting

abs# 188

**Mahvash A Goolam**Release of endogenous glutathione modulates CaSR sensitivity to extracellular Ca<sup>2+</sup> and L-amino acids

abs# 190

**David Tognarini**

Radiofrequency Echographic Multi-Spectrometry (REMS) Diagnostic and Numerical T-score Concordance Rates in Over 1,000 Australian Patients

abs# 192

**ANZBMS Plenary - Metabolic Regulation of Bone**

11:30AM - 12:15PM

Plenary Room 1 &amp; 2

Chairs: Matthias Walle &amp; Marc Wein

11:30 AM

**Geert Carmeliet**

Cell metabolism in skeletal cells: bystander or driver?

abs# 23

**ANZBMS selected oral abstracts**

12:15PM - 1:30PM

Plenary Room 1 &amp; 2

Chairs: Matthias Walle &amp; Marc Wein

12:15 PM

**Annelies Smit**Circadian glucocorticoid rhythm *timing* and *amplitude* regulate bone remodeling

abs# 24

12:30 PM

**Sandra Iuliano**

Implementing dietary improvements to reduce fracture risk in aged care residents

abs# 25

12:45 PM

**Paul H Anderson**

Vitamin D receptor ablation in mature osteoblasts causes hyperparathyroidism, hypervitaminosis D and osteomalacia during dietary calcium and phosphorus restriction

abs# 26

1:00 PM

**Belinda R Beck**

Ten years of research in practice confirms high intensity exercise as first line therapy for osteoporosis

abs# 27

1:15 PM

**Eugenie Macfarlane**

Timed glucocorticoid treatment prevents cartilage degeneration driven by chronic disruption of circadian rhythms in C57BL/6J mice

abs# 28



1:30 PM	<b>Ian Reid</b> Progressive Decline in Nonvertebral Fracture Incidence with Zoledronate Use >3 Years: Post Hoc Analysis of an RCT <i>abs# 29</i>	
<b>Lunch</b>		
1:30PM - 2:30PM		Trinity Mezzanine
<b>ECIC Lunchtime Symposium</b>		
1:30PM - 2:30PM		Plenary Room 1 & 2
<b>ANZBMS Symposium - Menopausal Hormone Therapy / Transgender and Bone Health</b>		
2:30PM - 3:30PM		Plenary Room 1 & 2
<i>Chairs: Kun (Kathy) Zhu &amp; Natalie Hyde</i>		
2:30 PM	<b>Rachel Davey</b> Gender Affirming Hormone Therapy (GAHT) and Bone Health: Insights from a Preclinical Model of Feminising Hormone Therapy <i>abs# 30</i>	
3:00 PM	<b>Bronwyn Stuckey</b> Menopausal hormone therapy for fracture prevention <i>abs# 31</i>	
<b>ANZBMS selected oral abstracts</b>		
3:30PM - 4:30PM		Plenary Room 1 & 2
<i>Chairs: Kun (Kathy) Zhu &amp; Natalie Hyde</i>		
3:30 PM	<b>Susan Millard</b> Macrophage iron overload as a driver of bone marrow dysfunction and skeletal aging <i>abs# 32</i>	
3:42 PM	<b>Kara Anderson</b> Perimenopausal bone mineral density but not rate of bone loss is associated with incident fracture <i>abs# 33</i>	
3:54 PM	<b>Haniyeh Hemmatian</b> Cortical bone in older women has greater collagen compaction and less osteocyte connectivity at the time of deposition <i>abs# 34</i>	
4:06 PM	<b>Dougall Norris</b> Osteoclast recycling as a potential mechanism driving rebound bone loss following denosumab withdrawal <i>abs# 35</i>	
4:18 PM	<b>Mícheál Ó Breasail</b> Sex- and compartment-specific deficits in volumetric bone mineral density (vBMD) and estimated bone strength among older people living with HIV (PLWH). <i>abs# 36</i>	
<b>Afternoon Tea &amp; Meet the Expert Session</b>		
4:30PM - 5:00PM		Trinity Mezzanine
'Meet the Expert' – Dr. John Schousbe		
<b>ANZBMS ECI B.O.N.E Symposium 1</b>		
5:00PM - 5:30PM		Plenary Room 1 & 2
<i>Chairs: Dzenita Muratovic &amp; Geert Carmeliet</i>		
5:00 PM	<b>Mikihito Hayashi</b> Generation of an osteocyte-specific Cre mouse model reveals distinct roles of osteocytes <i>abs# 37</i>	

## ANZBMS AGM

5:30PM - 6:30PM

Plenary Room 1 & 2

## Conference Dinner

7:30PM - 11:00PM

Rainforestation

Buses depart from the Cairns Convention Centre at 6.20pm to Rainforestation.

Shuttle buses will begin returning from Rainforestation at 11:00pm.

## Wednesday 12th November 2025

### Registration desk opens

8:30AM - 12:30PM

Registration M15

### ANZBMS ECI B.O.N.E Symposium 2

9:00AM - 9:30AM

Plenary Room 1 & 2

*Chairs: Jillian Cornish & Christian Girgis*

9:00 AM

**Matthias Walle**

*Bone Health in Microgravity: Tracking Bone Remodelling in Spaceflight and Recovery*

*abs# 38*

### Selected oral abstracts

9:30AM - 10:30AM

Plenary Room 1 & 2

*Chairs: Jillian Cornish & Christian Girgis*

9:30 AM

**Pholpat Durongbhan**

Time-lapse *in vivo* contrast-enhanced micro-computed tomography uncovers structural disease patterns of early post-traumatic osteoarthritis in a DMM mouse model

*abs# 39*

9:42 AM

**Kun (Kathy) Zhu**

Longitudinal associations of multimorbidity with physical function and risk of falling in middle-aged adults

*abs# 40*

9:54 AM

**Susumu Tashiro**

Bone regeneration using iPS cell-derived immortalized mesenchymal stem cells

*abs# 41*

10:06 AM

**Thach S Tran**

Postponement of fracture as a novel metric for expressing anti-fracture efficacy: An IPD meta-analysis

*abs# 42*

10:18 AM

**Chen Chen**

Nano-encapsulation of mānuka oil for bone loss associated with microbial Infection

*abs# 43*

### Morning Tea & Meet the Expert Session

10:30AM - 11:00AM

Trinity Mezzanine

'Meet the Expert' – Associate Professor Marc Wein

### Past Awardees

11:00AM - 11:15AM

Plenary Room 1 & 2

*Chairs: Eugenie Macfarlane & Ashim Sinha*

11:00 AM

**Lieke Scheepers**

Air pollution and bone health outcomes: Periods of susceptibility from pregnancy to childhood

*abs# 44*

## ANZBMS & Healthy Bones Australia Symposium - Indigenous Health

11:15AM - 12:15PM

Plenary Room 1 & 2

*Chair: Eugenie Macfarlane & Ashim Shinha*

11:15 AM Introduction: Greg Lyubomirsky, CEO of Healthy Bones Australia

11:25 AM **Agnes Mosby**  
Consumer Advocate Presentation

*abs# 45*

11:50 AM **Ayşe Zengin**  
Bone Health in the Australian Indigenous Population

*abs# 46*

### Lunch

12:30PM - 1:30PM

Trinity Mezzanine

- The aim of the SupportEd Osteoporosis Patient Program\* is to encourage your patients on Prolia® or CORORA® to return for their treatment **within 6 months** of their previous injection. The six-monthly treatment interval is very important, as bone loss may occur quickly if treatment is delayed or ceased<sup>1,2,3</sup>
- Arrotex will provide active patients enrolled on the SupportEd Osteoporosis Patient Program with a free supply of Vitamin D supplements†

## How it works:

**1**

Pharmacist dispenses Prolia® or CORORA® and enrolls patient on the **SupportEd Osteoporosis Patient Program**

**2**

Once the patient is enrolled, the pharmacist provides the patient a pack of **Chemist's Own Vitamin D3** (1000IU)



**3**

The **SupportEd Osteoporosis Patient Program** will send a reminder to the patient at **month 4** (8, 12, etc) to pick up their next Vitamin D supply from the pharmacy

**4**

Pharmacist provides Vitamin D replenishment and **gives a reminder prompt to patients for them to book an appointment with their GP or Specialist** for their script, before their 6 monthly injection is due. The patient will also receive SMS reminders to get their Prolia® or CORORA® script filled every 6 months.



**CORORA®**  
denosumab

**Prolia PBS information:** Authority required (STREAMLINED) as treatment for osteoporosis. Criteria Apply.  
Refer to PBS Schedule for full Authority Required information.

**CORORA PBS information:** Authority required (STREAMLINED) as treatment for osteoporosis. Criteria Apply.  
Refer to PBS Schedule for full Authority Required information.



**Please refer to the full PROLIA® Product Information**, available from Amgen Australia Pty Ltd (ph: 1800 803 638) or this QR Code.



**Please refer to the full CORORA® Product Information**, available from Amgen Australia Pty Ltd (ph: 1800 803 638) or this QR Code.

\*The SupportEd Osteoporosis Patient Program encompasses Arrotex's portfolio of osteoporosis medications

#Product images are illustrative and to be used as guide only.

† To reduce the risk of hypocalcaemia, patients must be adequately supplemented with calcium and vitamin D<sup>2,3</sup>

References: 1. Healthy Bones Australia. Position Statement on the Management of Osteoporosis, February 2023 2. Prolia (denosumab) Approved Product Information. 3. CORORA® (denosumab) Approved Product Information 4. Date on File, October 2025.

Prolia® and Corora® are registered trademarks of Amgen Australia Pty Ltd, Sydney NSW 2000. ABN 31 051 067 428. Amgen Medical Information: 1800 803 638. Phone: +61 2 9870 1333. www.amgen.com.au. AUS-162-25-80009. Arrotex Pharmaceuticals, Cremorne VIC 3121. ABN 30-605-552-234. Copyright ©2025 All rights reserved. PRESCRIPTION-004548. Date of preparation: October 2025

---

## POSTER LISTING

---

### PLENARY POSTERS (PLENARY ROOM 1 & 2)

**Dennis Chan**

Determinants of REMS Femoral Neck Fragility Score

*abs# 111*

**Anthony Dosseto**

Calcium Isotope Markers (CIM): A Novel Tool for Early Detection and Monitoring of Osteoporosis

*abs# 112*

**Pholpat Durongbhan**

Decoupling calcified cartilage from cortical bone reveals distinct mineralisation patterns in an osteoarthritis mouse model

*abs# 113*

**Abadi Gebre**

Automated abdominal aortic calcification and trabecular bone score independently predict incident fracture during routine osteoporosis screening

*abs# 114*

**Miki Maemura**

Regulation of Bone and Cartilage Metabolism by Supersulfides and Their Therapeutic Potential

*abs# 115*

**Luisa Rosi**

Bone health in heart transplantation: a Melbourne perspective revealed a higher rate of post-transplant fractures in females which occurred earlier than in males despite antiresorptive therapy and preserving bone density those who received it.

*abs# 116*

**Hideaki Sabe**

In Vivo Profiling of Osteoclast Gene Expression Using a Novel Binary Cre - RiboTag System

*abs# 117*

**Kenta Sawamura**

Meclozine and growth hormone ameliorate bone length and quality in experimental models of achondroplasia

*abs# 118*

**Angela Sheu**

3D Shaper in Monitoring Bone Loss in Lung Transplant Patients

*abs# 119*

**Kun (Kathy) Zhu**

DXA-measured visceral adipose tissue and accelerated biological ageing in middle-aged adults

*abs# 120*

### POSTER TOUR 1 - TOP 5 CLINICAL & BASIC SCIENCE POSTERS (TRINITY MEZZANINE)

4:30 PM **Kara B Anderson**

Associations between "peak bone mass" and later life bone density: Data from the Geelong Osteoporosis Study

*abs# 121*

4:33 PM **Agnieszka Arthur**

Concomitant spinal cord injury and traumatic brain injury impact bone remodelling, understanding the molecular changes through proteomic analysis.

*abs# 122*

4:36 PM **Melkamu Tamir Hunegnaw**

Effects of A Digital Voice Assistant-Delivered Osteoporosis Self-Management Program on Diet in Postmenopausal Women with Osteoporosis: A 12-Month Randomised Controlled Trial

*abs# 123*

4:39 PM **Benjamin H Mullin**

Genome-wide association study meta-analysis identifies association of a locus containing the vitamin D 24-hydroxylase gene (CYP24A1) with bone mineral density

*abs# 124*

4:42 PM **Yukiko Noguchi**

Hard tissue-forming ability of alpha-smooth muscle actin-positive cells in dental pulp

*abs# 125*

---

ANZBMS Annual Scientific Meeting Delegate Booklet 2025

32 | Page

Digital Delegate Handbook sponsored by:



4:45 PM **Ken Qu**

Making the first fracture the last fracture Examining the efficacy of the Westmead Hospital Fracture Liaison Service in reducing re-fractures over 3 years *abs# 126*

4:48 PM **David Scott**

Feasibility, safety and efficacy of OsteoStrong® in postmenopausal women with low bone mineral density *abs# 127*

4:51 PM **Nick Tran**

*"Skeletal Age" for cumulative impact of cigarette smoking on post-fracture mortality* *abs# 128*

4:54 PM **Yuandan Zhang**

Genetic differences between abdominal aortic and coronary artery calcification and implications for vascular disease and adverse health outcomes *abs# 129*

4:57 PM **Yinghong Zhou**

Melatonin Promotes Osteogenesis but Activates TLR4-Mediated Osteoclastogenesis in a Dose-Dependent Manner *abs# 130*

## **ANZBMS POSTER SESSION 1 - ODD NUMBERS (TRINITY MEZZANINE)**

**Kara B Anderson**

Fracture rates decline during COVID-19 lockdowns *abs# 141*

**Daniel Bennett**

Fracture Prophylaxis for Adult Lung Transplant Recipients: a clinical audit of fracture risk identification and prevention *abs# 143*

**Nathan Cheuk**

Hypercalcaemia in a tiger man *abs# 145*

**Hannah Cunningham**

Challenges in management of low bone density in a young man with malabsorption and recurrent iron infusions *abs# 147*

**Zoe Gavey**

Rock solid but fragile: a case of autosomal dominant osteopetrosis *abs# 149*

**Ali Ghasem-Zadeh**

Patients With Chronic Kidney Disease Have Accelerated Microarchitectural Bone Deterioration *abs# 151*

**Amy T Harding**

What outcomes matter to people living with or at risk of minimal trauma fracture? Findings from the 'Measures that Matter' survey *abs# 153*

**Evelyn Hao**

Bone health screening in patients with type 2 diabetes mellitus - a single-centre retrospective audit *abs# 155*

**Natalie K Hyde**

The reliability of neonatal screening for developmental dysplasia of the hip in a regional service: How many cases are we not capturing? *abs# 157*

**Annabelle Kimmorley**

Running on empty: assessing the cost of low energy availability on female athlete bone health through quantitative ultrasound *abs# 159*

**Siehoon Lah**

Bone Mineral Density Changes After Liver Transplantation: Experience from A Tertiary Transplant Unit *abs# 161*



<b>Paul Lawton</b>	
Giant Cells, Giant Questions: Denosumab Therapy in Central Giant Cell Granuloma	<i>abs# 163</i>
<b>Sarina LIM</b>	
Ten years clinical experience of bone health in aging transgender women from a single practice	<i>abs# 165</i>
<b>Yosuke Mano</b>	
The impact of metabolic syndrome on changes in trunk muscle cross-sectional area: a 10-year longitudinal study.	<i>abs# 167</i>
<b>Anna Maria Markarian</b>	
Profiling Tibial Cortical BMD Gradients: Associations with Body Composition in Childhood Cancer Survivors and Controls	<i>abs# 169</i>
<b>Joel Olney</b>	
Education of Junior Medical Officers Improves Identification and Accurate Coding of Osteoporotic Fractures	<i>abs# 171</i>
<b>Lai-Ming Kathleen Pak</b>	
Denosumab followed by romosozumab significantly improved bone density but did not prevent rebound vertebral fractures – A Case Report	<i>abs# 173</i>
<b>Julie A Pasco</b>	
Mood disorder and Bone Material Strength Index in women	<i>abs# 175</i>
5:00 PM <b>Ahmed Al Saeedi</b>	
A novel role of CXXC Finger Protein1 in calvarias development and osteoblast differentiation	<i>abs# 193</i>
<b>Dishan Samaranayake</b>	
Beyond the jaw: teriparatide in the management of bilateral external auditory canal osteonecrosis	<i>abs# 177</i>
<b>Angela Sheu</b>	
DXA based 3-dimensional (3D) modelling technology to examine differential bone loss following heart transplantation	<i>abs# 179</i>
<b>Andrea Sit</b>	
Skeletons in the closet: Missed opportunities to institute osteoporosis therapy after minimal trauma fractures – a single-centre retrospective audit	<i>abs# 181</i>
<b>David Tognarini</b>	
Relationship Between REMS-Derived Fragility Score, Age and Bone Mineral Density in Australian Patients	<i>abs# 183</i>
<b>Julia JT Tsolakis</b>	
Beware the rebound when breaking up with denosumab	<i>abs# 185</i>
<b>King Ho Wong</b>	
Biannual Bone Bolstering Business - Insights from Following Up Continuation of Denosumab as Management of Clinical Osteoporosis at a Major Trauma Centre	<i>abs# 187</i>
<b>Damian Wu</b>	
Trabecular bone score in lung transplant recipients	<i>abs# 189</i>
<b>Daheng Xia</b>	
A Case of Bilateral External Auditory Canal Osteonecrosis and Novel Treatment with Teriparatide	<i>abs# 191</i>

## POSTER TOUR 2 - TOP 5 CLINICAL & BASIC SCIENCE POSTERS (TRINITY MEZZANINE)

10:00 AM **Kara B Anderson**

Incidence of vertebral fracture in a cohort of Australian women: Data from the Geelong Osteoporosis Study *abs# 131*

10:03 AM **Ghsaq Alhamdani**

Collagen-based constructs for periodontal disease and bone regeneration *abs# 132*

10:06 AM **Mícheál Ó Breasail**

Rural-urban differences in osteoporosis and sarcopenia prevalence among Gambian older adults: A pilot study *abs# 133*

10:09 AM **Cherie Chiang**

Myeloma screen has poor yield as part of secondary osteoporosis screen *abs# 134*

10:12 AM **Terrence Diamond**

Negative impact of pelvic radiotherapy on bone mineral density in women treated with gynaecological malignancies *abs# 135*

10:15 AM **Kaitlyn A Flynn**

Evaluating the utility of zebrafish scales to model cellular and genetic determinants of human bone health *abs# 136*

10:18 AM **Annelies E Smit**

Developing a preclinical model to distinguish inflammation- and glucocorticoid-driven bone loss in the context of arthritis *abs# 137*

10:21 AM **Tahnee Thatcher**

Early Trabecular Bone Microarchitecture Deficits in a Female Mouse Model of Parkinson's Disease. *abs# 138*

10:24 AM **Owen Taylor-Williams**

Revision Risk Following Primary Total Hip Arthroplasty in Australian Rheumatoid Arthritis Patients *abs# 139*

10:27 AM **Shinji Yamada**

Prevalence and Incidence of Vertebral Fractures in Middle-aged and Older Working Men: A Cross-sectional and Longitudinal Study *abs# 140*

## ANZBMS POSTER SESSION 2 - EVEN NUMBERS & NORDIN POSTER VIEWING (TRINITY MEZZANINE)

**Kara B Anderson**

Advanced Paternal Age and Offspring Bone Health in Adulthood; Do Associations Reported in Childhood Persist? *abs# 142*

**Kara Anderson**

Psychotropic medication use and bone loss in men *abs# 144*

**Denekew Tenaw Anley**

Title: Menopause-related bone loss in women living with HIV: A systematic review *abs# 146*

**Daisuke Arakawa**

[4-(Methylthio) phenylthio] methane bisphosphonate (MPMBP) prevents deterioration of bone microarchitecture, reduction of soleus muscle mass, and increase of visceral fat in elastase-induced emphysema mice *abs# 148*

**Sarah C Brennan**

Anabolic effects of romosozumab in an Australian context with notable prior anti-resorptive treatment *abs# 150*

**Dimitrios DC Cakouros**

The interplay between histone/DNA modifying enzymes and metabolites in regulating bone aging and metabolism *abs# 152*

<b>Christopher Chan</b>	
Systemic mastocytosis and osteoporosis - a clinical case and review of the literature	<i>abs# 154</i>
<b>Lai-Ming Kathleen Pak</b>	
Unexplained Fragility Fractures and Elevated IgE: Two Cases Suggesting Hyper-IgE Syndrome and a Novel Adverse Reaction to Romosozumab	<i>abs# 156</i>
<b>Jack Dalla Via</b>	
Co-designing a digital health tool to support self-management of hypophosphatasia in adults	<i>abs# 158</i>
<b>Michael Fogarty</b>	
B6 toxicity: an important hypocalcaemia mimic	<i>abs# 160</i>
<b>Kirtan Ganda</b>	
Assessing Protocolisation of Hypophosphataemia Screening in High-Risk Patients Receiving Parenteral Iron	<i>abs# 162</i>
<b>Natalie K Hyde</b>	
Risk of fracture in adulthood is associated with childhood fracture history independent of bone mineral density in women: The Geelong Osteoporosis Study	<i>abs# 164</i>
<b>Amanda Ji</b>	
Multiple paragangliomas and osteoporosis in a patient with DNMT3A mutation: a new association	<i>abs# 166</i>
<b>Brintha Krishnamoorthi</b>	
“Deadly double-trouble” – life-threatening hypocalcaemia following denosumab and parenteral iron administration	<i>abs# 168</i>
<b>Siehoon Lah</b>	
Laxative misuse resulting in hypercalcaemia with inappropriately normal parathyroid hormone levels and digital clubbing: A case series	<i>abs# 170</i>
<b>Annabel Lee</b>	
Challenges in managing hypercalcaemia in pregnancy: two case reports	<i>abs# 172</i>
<b>Anna Maria Markarian</b>	
Zoledronic Acid in Pediatric Acute Lymphoblastic Leukemia Management: A Case Report of Region-Specific Bone Recovery	<i>abs# 174</i>
<b>Renae Beardmore</b>	
Out of the shadow: Transforming care for people living with hypophosphatasia	<i>abs# 176</i>
<b>Julie A Pasco</b>	
Intrinsic capacity and sarcopenia: data from the Geelong Osteoporosis Study	<i>abs# 178</i>
<b>Charlotte Piesse</b>	
A case of Gnathodiaphyseal Dysplasia/“High Bone Mass Osteogenesis Imperfecta” due to novel COL1A1 mutation	<i>abs# 180</i>
<b>Alexander Rodriguez</b>	
A randomised controlled trial of vitamin D combined with exercise on arterial stiffness in vitamin D deficient, overweight/obese older adults	<i>abs# 182</i>
<b>Owen Taylor-Williams</b>	
The Effect of Modern Pharmacotherapy on Bone Mineral Density in Rheumatoid Arthritis Patients	<i>abs# 184</i>
<b>Mina Toumas</b>	
Congenital Hypogonadotrophic Hypogonadism with FGFR1 mutation and progressive decline in bone mineral density.	<i>abs# 186</i>

**Aminu Suleiman**

Healthy Ageing Without Major Osteoporotic Fracture or Joint Replacement Surgery: A Time-Dependent Competing Risks Analysis Using Inverse Probability Weighting *abs# 188*


**Mahvash A Goolam**

Release of endogenous glutathione modulates CaSR sensitivity to extracellular  $\text{Ca}^{2+}$  and L-amino acids *abs# 190*

**David Tognarini**

Radiofrequency Echographic Multi-Spectrometry (REMS) Diagnostic and Numerical T-score Concordance Rates in Over 1,000 Australian Patients *abs# 192*

## SPONSOR AND TRADE PARTICIPANTS



Booth 1 – 4	Arrotex Pharmaceuticals
Booth 5	Hologic
Booth 6	Alexion Pharma
Booth 8	Theramex
Booth 9 & 12	AMGEN
Booth 10 & 11	Kyowa Kirin

## PLATINUM SPONSOR

### Arrotex Pharmaceuticals

Booth 1,2,3,4

Arrotex Pharmaceuticals is the largest Australian pharmaceutical company, proudly Australian-founded and headquartered in Melbourne. Supplying one in every two PBS prescriptions<sup>1-4</sup> dispensed nationally, Arrotex is a trusted leader in delivering access to affordable, high-quality medicines and healthcare solutions for all Australians.

With an extensive range of prescription products across the full spectrum of therapeutic areas, Arrotex plays a vital role in supporting clinicians, pharmacists, and patients in managing chronic and prevalent health conditions, including osteoporosis and other bone and mineral disorders.

Arrotex is committed to improving outcomes for people living with osteoporosis through the SupportEd Osteoporosis Patient Program\* - a national initiative designed to empower patients with education, motivation, and ongoing support to stay on treatment. To date, the program has enrolled and supported more than 260,000 Australian patients<sup>4</sup>, helping them better understand their condition, adhere to therapy, and improve long-term bone health outcomes.

Our commitment extends beyond medicines. Arrotex engages in key partnerships to raise awareness of osteoporosis, encourage early intervention, and strengthen continuity of care. Through these collaborations, we aim to make meaningful contributions to improved diagnoses, treatment adherence, and quality of life for people with osteoporosis and related conditions.

With deep local expertise, strong commercial infrastructure, and a mission to enhance health equity, Arrotex continues to drive access, innovation, and sustainability across Australia's healthcare system, ensuring more Australians can live stronger, healthier lives for longer.

\*The SupportEd Osteoporosis Patient Program encompasses Arrotex's portfolio of osteoporosis medications

REFERENCES: 1. IQVIA MAT May 2025, Prescription SKUs; 2. PBS Expenditure and Prescriptions report 1 July 2023 to 30 June 2024 2. Table 12(c): Top 20 Responsible Persons by Total PBS Prescriptions, 2023-24. 3. IQVIA MAT June 2024. 4. Data on file, October 2025.

## GOLD SPONSOR

### Kyowa Kirin

Booth 10,11

Kyowa Kirin Co., Ltd. is a research-based life sciences company, with special strengths in biotechnologies. We strive to understand the unmet needs of patients with rare diseases to bring a profound and positive impact to their journey. Kyowa Kirin Australia is focussed on delivering a unique pipeline of medicines to Australian patients with unmet rare disease needs. Currently, our main area of focus is X-linked hypophosphataemia (XLH), a rare, genetic, and progressive disease. You can learn more about the business at [www.kyowakirin.com/australia](http://www.kyowakirin.com/australia).

## SILVER SPONSOR

### AMGEN

Booth 9, 12

Our Mission: To Serve Patients

Amgen harnesses the best of biology and technology to fight the world's toughest diseases, and make people's lives easier, fuller and longer. We helped establish the biotechnology industry more than 40 years ago and remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

#### REACHING SERIOUSLY ILL PATIENTS WORLDWIDE

We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on four therapeutic areas: general medicine, rare disease, inflammation and oncology, delivering innovative medicines to help people live longer, fuller, happier lives.

#### ACCELERATING THERAPIES FOR PATIENTS WITH CUTTING-EDGE SCIENCE

We combine our understanding of human genetics and disease biology with advanced science and technologies, like protein engineering and AI capabilities, to identify and deliver the most effective treatments for people living with some of the world's toughest diseases.

## COFFEE CART SPONSOR

### Kyowa Kirin

**Booth 10,11**

Kyowa Kirin Co., Ltd. is a research-based life sciences company, with special strengths in biotechnologies. We strive to understand the unmet needs of patients with rare diseases to bring a profound and positive impact to their journey. Kyowa Kirin Australia is focussed on delivering a unique pipeline of medicines to Australian patients with unmet rare disease needs. Currently, our main area of focus is X-linked hypophosphataemia (XLH), a rare, genetic, and progressive disease. You can learn more about the business at [www.kyowakirin.com/australia](http://www.kyowakirin.com/australia).

### Arrotex Pharmaceuticals

**Booth 1,2,3,4**

Arrotex Pharmaceuticals is the largest Australian pharmaceutical company, proudly Australian-founded and headquartered in Melbourne. Supplying one in every two PBS prescriptions<sup>1-4</sup> dispensed nationally, Arrotex is a trusted leader in delivering access to affordable, high-quality medicines and healthcare solutions for all Australians.

With an extensive range of prescription products across the full spectrum of therapeutic areas, Arrotex plays a vital role in supporting clinicians, pharmacists, and patients in managing chronic and prevalent health conditions, including osteoporosis and other bone and mineral disorders.

Arrotex is committed to improving outcomes for people living with osteoporosis through the SupportEd Osteoporosis Patient Program\* - a national initiative designed to empower patients with education, motivation, and ongoing support to stay on treatment. To date, the program has enrolled and supported more than 260,000 Australian patients<sup>4</sup>, helping them better understand their condition, adhere to therapy, and improve long-term bone health outcomes.

Our commitment extends beyond medicines. Arrotex engages in key partnerships to raise awareness of osteoporosis, encourage early intervention, and strengthen continuity of care. Through these collaborations, we aim to make meaningful contributions to improved diagnoses, treatment adherence, and quality of life for people with osteoporosis and related conditions.

With deep local expertise, strong commercial infrastructure, and a mission to enhance health equity, Arrotex continues to drive access, innovation, and sustainability across Australia's healthcare system, ensuring more Australians can live stronger, healthier lives for longer.

\*The SupportEd Osteoporosis Patient Program encompasses Arrotex's portfolio of osteoporosis medications

REFERENCES: 1. IQVIA MAT May 2025, Prescription SKUs; 2. PBS Expenditure and Prescriptions report 1 July 2023 to 30 June 2024 2. Table 12(c): Top 20 Responsible Persons by Total PBS Prescriptions, 2023-24. 3. IQVIA MAT June 2024. 4. Data on file, October 2025.

## EXHIBITORS

### Alexion Pharma

**Booth 6**

Alexion, Astra Zeneca Rare Diseases, has been a leader in rare diseases for more than 30 years. Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. We work alongside healthcare providers, patient advocacy organisations and governments to best serve patients by innovating and expanding our knowledge of rare diseases. Our goal is to bring hope to patients and families by delivering scientific advances.

AU/NP/0003

### Hologic

**Booth 5**

Hologic's purpose is to empower people to live healthier lives everywhere, every day.

As a champion for women's health, Hologic helps healthcare professionals diagnose and treat their patients with precision, certainty, and confidence. Hologic innovations are designed to achieve exceptional clinical results, to detect, diagnose and treat earlier and more effectively.



**Theramex****Booth 8**

Theramex Australia is a specialty pharmaceutical company solely committed to supporting the health needs of women. By working closely with our partners and healthcare professionals, Theramex Australia provides a diverse portfolio of treatments that help women through life's stages.